Journal of Heart and Lung Transplantation

Papers
(The TQCC of Journal of Heart and Lung Transplantation is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal1214
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation317
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report — 2021; Focus on recipient charact228
A 5-year single-center early experience of heart transplantation from donation after circulatory-determined death donors157
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult heart transplantation report—2020; focus on deceased donor characterist148
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report — 2021; Focus on recipient charac137
First cases of COVID-19 in heart transplantation from China134
BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response110
Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry110
Early US experience with cardiac donation after circulatory death (DCD) using normothermic regional perfusion106
Donor heart and lung procurement: A consensus statement103
Updated definitions of adverse events for trials and registries of mechanical circulatory support: A consensus statement of the mechanical circulatory support academic research consortium102
Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients101
The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients92
Early experience with the HeartMate 3 continuous-flow ventricular assist device in pediatric patients and patients with congenital heart disease: A multicenter registry analysis86
Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience77
MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry75
COVID-19: Yet another coronavirus challenge in transplantation70
Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant66
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult lung transplantation report — 2020; focus on deceased donor characteris61
Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial59
Donor fraction cell-free DNA and rejection in adult and pediatric heart transplantation58
Epidemiologic and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: A descriptive survey report58
Pig-to-non-human primate heart transplantation: The final step toward clinical xenotransplantation?56
Circulating extracellular vesicles as non-invasive biomarker of rejection in heart transplant56
Artificial intelligence for early prediction of pulmonary hypertension using electrocardiography55
Mortality in patients with cardiogenic shock supported with VA ECMO: A systematic review and meta-analysis evaluating the impact of etiology on 29,289 patients54
SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients50
Utilization of hepatitis C virus–infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement49
Heart transplantation following donation after circulatory death: Expanding the donor pool48
COVID-19 vaccination in our transplant recipients: The time is now47
Impact of left ventricular assist device implantation on mitral regurgitation: An analysis from the MOMENTUM 3 trial47
Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system45
International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation45
The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update44
Update to an early investigation of outcomes with the new 2018 donor heart allocation system in the United States43
The impact of frailty on mortality after heart transplantation42
ISHLT consensus statement for the selection and management of pediatric and congenital heart disease patients on ventricular assist devices Endorsed by the American Heart Association40
Berlin Heart EXCOR and ACTION post-approval surveillance study report40
Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study39
Increased early acute cellular rejection events in hepatitis C-positive heart transplantation39
Systemic ventricular assist device support in Fontan patients: A report by ACTION38
Lung transplantation for cystic fibrosis36
Coronavirus disease 2019 in heart transplant recipients: Risk factors, immunosuppression, and outcomes36
Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT36
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-ninth adult lung transplantation report—2022; focus on lung transplant reci36
Right ventricular function and cardiopulmonary performance among patients with heart failure supported by durable mechanical circulatory support devices35
Improved survival after heart transplantation in patients bridged with extracorporeal membrane oxygenation in the new allocation system35
COVID-19 in a lung transplant recipient34
The results of a single-center experience with HeartMate 3 in a biventricular configuration33
First in man evaluation of a novel circulatory support device: Early experience with the Impella 5.5 after CE mark approval in Germany33
Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study32
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric heart transplantation report — 2021; focus on recipient ch32
Is it too early to investigate survival outcomes of the new US heart allocation system?32
Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy32
COVID-19 in a pediatric heart transplant recipient: Emergence of donor-specific antibodies31
Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension30
Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 Task Force statement30
Outcomes in the 2018 UNOS donor heart allocation system: A perspective on disparate analyses30
Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial30
Pregnancy outcomes in heart transplant recipients30
Donor heart selection: Evidence-based guidelines for providers29
Cell-free DNA beyond a biomarker for rejection: Biological trigger of tissue injury and potential therapeutics29
Less invasive surgical implant strategy and right heart failure after LVAD implantation29
Mitochondrial transplantation for myocardial protection in ex-situ‒perfused hearts donated after circulatory death29
Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD)28
Pregnancy in pulmonary arterial hypertension: Midterm outcomes of mothers and offspring28
Cell death and ischemia-reperfusion injury in lung transplantation27
Prediction of donor related lung injury in clinical lung transplantation using a validated ex vivo lung perfusion inflammation score27
Expanding Heart Transplants from Donors After Circulatory Death (DCD) - Results of the First Randomized Controlled Trial Using the Organ Care System (OCS™) Heart - (OCS DCD Heart Trial)26
Incidence and impact of primary graft dysfunction in adult heart transplant recipients: A systematic review and meta-analysis26
The International Society for Heart and Lung Transplantation/Heart Failure Society of America Guideline on Acute Mechanical Circulatory Support26
Clinical outcomes and healthcare expenditures in the real world with left ventricular assist devices – The CLEAR-LVAD study26
A case series of novel coronavirus infection in heart transplantation from 2 centers in the pandemic area in the North of Italy26
Long-term outcomes after intraoperative extracorporeal membrane oxygenation during lung transplantation26
Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension26
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 23rd pediatric heart transplantation report—2020; focus on deceased donor characte26
COVID-19 vaccination immune paresis in heart and lung transplantation25
Challenges in heart transplantation during COVID-19: A single-center experience25
Circulating exosomes with lung self-antigens as a biomarker for chronic lung allograft dysfunction: A retrospective analysis25
Ex situ heart perfusion: The past, the present, and the future24
Clinical myocardial recovery in advanced heart failure with long term left ventricular assist device support24
The International thoracic organ transplant registry of the international society for heart and lung transplantation: Thirty-ninth adult heart transplantation report—2022; focus on transplant for rest24
Percutaneous versus surgical cannulation for femoro-femoral VA-ECMO in patients with cardiogenic shock: Results from the Extracorporeal Life Support Organization Registry24
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric lung transplantation report — 2021; Focus on recipient cha23
Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes23
Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort23
Bridging the survival gap in cystic fibrosis: An investigation of lung transplant outcomes in Canada and the United States23
Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment22
International consensus recommendations for anesthetic and intensive care management of lung transplantation. An EACTAIC, SCA, ISHLT, ESOT, ESTS, and AST approved document22
Comparison of combined heart‒liver vs heart-only transplantation in pediatric and young adult Fontan recipients22
Clinical utility of donor-derived cell-free DNA testing in cardiac transplantation22
Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis22
Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction22
Serial right heart catheter assessment between balloon pulmonary angioplasty sessions identify procedural factors that influence response to treatment22
Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care21
A novel method of donor‒recipient size matching in pediatric heart transplantation: A total cardiac volume‒predictive model21
Long-term survival on LVAD support: Device complications and end-organ dysfunction limit long-term success21
Transplanting thoracic COVID-19 positive donors: An institutional protocol and report of the first 14 cases21
Risk factors for mortality in lung transplant recipients aged ≥65 years: A retrospective cohort study of 5,815 patients in the scientific registry of transplant recipients21
Impact of carfilzomib-based desensitization on heart transplantation of sensitized candidates21
Collapsing glomerulopathy associated with COVID-19 infection in a heart transplant recipient21
Bronchoalveolar bile acid and inflammatory markers to identify high-risk lung transplant recipients with reflux and microaspiration20
Gender and racial disparities in lung transplantation in the United States20
Preservation by cold storage vs ex vivo normothermic perfusion of marginal donor hearts: clinical, histopathologic, and ultrastructural features20
Circulating miR-181a-5p as a new biomarker for acute cellular rejection in heart transplantation20
Epicardial transplantation of atrial appendage micrograft patch salvages myocardium after infarction20
Elevated pulmonary arterial elastance and right ventricular uncoupling are associated with greater mortality in advanced heart failure20
Azithromycin prophylaxis after lung transplantation is associated with improved overall survival20
CFTR modulator use in post lung transplant recipients20
Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study20
Clinical impact of concomitant tricuspid valve procedures during left ventricular assist device implantation20
Therapeutic efficacy of large aligned cardiac tissue derived from induced pluripotent stem cell in a porcine ischemic cardiomyopathy model19
Pig heart and lung xenotransplantation: Present status19
Percutaneous RVAD with the Protek Duo for severe right ventricular primary graft dysfunction after heart transplant19
Ex vivo treatment of cytomegalovirus in human donor lungs using a novel chemokine-based immunotoxin19
Risk factors of invasive fungal infections in lung transplant recipients: A systematic review and meta-analysis19
A novel donor-derived cell-free DNA assay for the detection of acute rejection in heart transplantation19
Clinical characteristics, management practices, and outcomes among lung transplant patients with COVID-1919
Reproductive health after thoracic transplantation: An ISHLT expert consensus statement18
Lung transplantation for idiopathic pulmonary fibrosis enriches for individuals with telomere-mediated disease18
Recipient and surgical factors trigger severe primary graft dysfunction after heart transplant18
Use of metabolomics to identify strategies to improve and prolong ex vivo lung perfusion for lung transplants18
Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary Hypertension18
Aspiration of conjugated bile acids predicts adverse lung transplant outcomes and correlates with airway lipid and cytokine dysregulation18
Arterial oxygen and carbon dioxide tension and acute brain injury in extracorporeal cardiopulmonary resuscitation patients: Analysis of the extracorporeal life support organization registry18
Venous or arterial thromboses after venoarterial extracorporeal membrane oxygenation support: Frequency and risk factors17
ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery17
Innate allorecognition in transplantation17
Molecular T-cell‒mediated rejection in transbronchial and mucosal lung transplant biopsies is associated with future risk of graft loss17
The International thoracic organ transplant registry of the international society for heart and lung transplantation: Twenty-fifth pediatric heart transplantation report—2022; focus on infant heart tr17
Quantifying the impact from stroke during support with continuous flow ventricular assist devices: An STS INTERMACS analysis17
Outcomes based on blood pressure in patients on continuous flow left ventricular assist device support: An Interagency Registry for Mechanically Assisted Circulatory Support analysis17
Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review17
A current era analysis of ABO incompatible listing practice and impact on outcomes in young children requiring heart transplantation17
Glycation of ryanodine receptor in circulating lymphocytes predicts the response to cardiac resynchronization therapy17
The effect of COVID-19 on transplant function and development of CLAD in lung transplant patients: A multicenter experience17
The lung microbiome in lung transplantation17
Incidence and long-term outcome of heart transplantation patients who develop postoperative renal failure requiring dialysis17
Outcomes after heart transplantation and total artificial heart implantation: A multicenter study16
The influence of mechanical Circulatory support on post-transplant outcomes in pediatric patients: A multicenter study from the International Society for Heart and Lung Transplantation (ISHLT) Registr16
Adenosine A2A receptor agonist (regadenoson) in human lung transplantation16
Initial bridge to transplant experience with a bioprosthetic autoregulated artificial heart16
An extracellular oxygen carrier during prolonged pulmonary preservation improves post-transplant lung function16
Successful salvage therapy for fungal bronchial anastomotic infection after –lung transplantation with an inhaled triazole anti-fungal PC94516
Surveillance for cardiac allograft vasculopathy: Practice variations among 50 pediatric heart transplant centers16
Exercise right ventricular ejection fraction predicts right ventricular contractile reserve16
Influence of the donor history of tobacco and marijuana smoking on early and intermediate lung transplant outcomes16
Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis16
Rotational thromboelastometry reduces blood loss and blood product usage after lung transplantation15
A challenge to equity in transplantation: Increased center-level variation in short-term mechanical circulatory support use in the context of the updated U.S. heart transplant allocation policy15
Pediatric heart transplantation following donation after circulatory death, distant procurement, and ex-situ perfusion15
Predicted heart mass–based size matching among recipients with moderate pulmonary hypertension: Outcomes and sex effect15
Complications of balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: Impact on the outcome15
Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: Analysis of ISHLT Registry15
Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry15
MicroRNA-206 antagomiR‒enriched extracellular vesicles attenuate lung ischemia‒reperfusion injury through CXCL1 regulation in alveolar epithelial cells15
Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?15
Dilemma of organ donation in transplantation and the COVID-19 pandemic15
Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients15
ISHLT position paper on thoracic organ transplantation in controlled donation after circulatory determination of death (cDCD)15
Risk assessment in severe pulmonary hypertension due to interstitial lung disease15
A CLUE for better assessment of donor lungs: Novel technique in clinical ex vivo lung perfusion15
The impaired diaphragmatic function after bilateral lung transplantation: A multifactorial longitudinal study15
Lactate during ex-situ heart perfusion does not predict the requirement for mechanical circulatory support following donation after circulatory death (DCD) heart transplants14
Ventilation in the prone position improves oxygenation and results in more lungs being transplanted from organ donors with hypoxemia and atelectasis14
Two-year outcome of warfarin monotherapy in HeartMate 3 left ventricular assist device: A single-center experience14
Right ventricular adaptation to pressure-overload: Differences between chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension14
Donor derived cell free DNA% is elevated with pathogens that are risk factors for acute and chronic lung allograft injury14
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-third pediatric lung transplantation report — 2020; focus on deceased donor14
Bronchiolitis obliterans syndrome is associated with increased senescent lymphocytes in the small airways14
High torque tenovirus (TTV) load before first vaccine dose is associated with poor serological response to COVID-19 vaccination in lung transplant recipients14
Myocardial edema in COVID-19 on cardiac MRI14
Effects of cold or warm ischemia and ex-vivo lung perfusion on the release of damage associated molecular patterns and inflammatory cytokines in experimental lung transplantation14
Early United States experience with lung donation after circulatory death using thoracoabdominal normothermic regional perfusion14
Impact of thoracotomy approach on right ventricular failure and length of stay in left ventricular assist device implants: an intermacs registry analysis14
Immune checkpoint inhibitors in heart or lung transplantation: Early results from a registry initiative14
Contemporary trends in PGD incidence, outcomes, and therapies14
Extended post ex-vivo lung perfusion cold preservation predicts primary graft dysfunction and mortality: Results from a multicentric study14
Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age14
Operating room extubation: A predictive factor for 1-year survival after double-lung transplantation13
Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients13
Remote ex vivo lung perfusion at a centralized evaluation facility13
Early report from the Pediatric Heart Transplant Society on COVID-19 infections in pediatric heart transplant candidates and recipients13
Right ventricular area strain from 3-dimensional echocardiography: Mechanistic insight of right ventricular dysfunction in pediatric pulmonary hypertension13
Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension13
Monitoring of perfusion quality and prediction of donor heart function during ex-vivo machine perfusion by myocardial microcirculation versus surrogate parameters13
A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: A United Kingdom perspective13
Biology of myocardial recovery in advanced heart failure with long-term mechanical support13
Lung transplantation using allografts with more than 8 hours of ischemic time: A single-institution experience13
Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial13
Indications and outcome after lung transplantation in children under 12 years of age: A 16-year single center experience13
Pulmonary artery pulsatility index as a predictor of right ventricular failure in left ventricular assist device recipients: A systematic review13
Understanding risk factors and predictors for stroke subtypes in the ENDURANCE trials13
Temporal shift and predictive performance of machine learning for heart transplant outcomes13
Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations13
Machine-learning–based exploration to identify remodeling patterns associated with death or heart-transplant in pediatric-dilated cardiomyopathy12
COVID-19 leading to acute encephalopathy in a patient with heart transplant12
Preventing alloimmune rejection using circular RNA FSCN1-silenced dendritic cells in heart transplantation12
Stroke in pediatric ventricular assist device patients—a pedimacs registry analysis12
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence12
Lung transplant outcome following donation after euthanasia12
International experience using a durable, centrifugal-flow ventricular assist device for biventricular support12
Racial and socioeconomic disparities in pediatric heart transplant outcomes in the era of anti-thymocyte globulin induction12
The impact of pre-implant illness severity on the outcomes of pediatric patients undergoing durable ventricular assist device12
Donor thyroid hormone therapy and heart transplantation outcomes: ISHLT transplant registry analysis12
A simplified strategy for donor-recipient size-matching in lung transplant for interstitial lung disease12
Innate immunity in lung transplantation12
Unmasking right ventricular-arterial uncoupling during fluid challenge in pulmonary hypertension12
Evaluation of 10°C as the optimal storage temperature for aspiration-injured donor lungs in a large animal transplant model12
ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, an12
Proteomic profiling identifies CLEC4C expression as a novel biomarker of primary graft dysfunction after heart transplantation12
Interplay of sex hormones and long-term right ventricular adaptation in a Dutch PAH-cohort12
Higher levels of allograft injury in black patients early after heart transplantation12
Heart transplantation outcomes in cardiac sarcoidosis12
Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation12
LVAD decommissioning for myocardial recovery: Long-term ventricular remodeling and adverse events12
Development of the Lung Transplant Frailty Scale (LT-FS)12
Thoracoabdominal normothermic regional perfusion in donation after circulatory death does not restore brain blood flow12
Risk assessment in pulmonary hypertension based on routinely measured laboratory parameters12
Factors contributing to exercise capacity in chronic thromboembolic pulmonary hypertension with near-normal hemodynamics11
Inflammatory responses in lungs from donation after brain death: Mechanisms and potential therapeutic targets11
Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension11
High-intensity interval training in patients with left ventricular assist devices: A pilot randomized controlled trial11
Precise treatment of acute antibody-mediated cardiac allograft rejection in rats using C4d-targeted microbubbles loaded with nitric oxide11
Idiopathic pulmonary arterial hypertension patients with a high H2FPEF-score: Insights from the Amsterdam UMC PAH-cohort11
Right single lung transplantation or double lung transplantation compared with left single lung transplantation in chronic obstructive pulmonary disease11
Resolution of post-lung transplant ischemia-reperfusion injury is modulated via Resolvin D1-FPR2 and Maresin 1-LGR6 signaling11
WITHDRAWN: Executive Summary - The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients11
Bridging to transplant with HeartMate 3 left ventricular assist devices in the new heart organ allocation system: An individualized approach11
The introduction of a super-urgent heart allocation scheme in the UK: A 2-year review11
Putting ethics and clinical decision making before politics: requiring COVID-19 immunization for Solid Organ Transplantation (SOT) Candidates and their Support Team11
Improved clinical outcomes associated with the Impella 5.5 compared to the Impella 5.0 in contemporary cardiogenic shock and heart failure patients11
Temporal trends in the use and outcomes of temporary mechanical circulatory support as a bridge to cardiac transplantation in Spain. Final report of the ASIS-TC study11
The heart–gut microbiome axis in advanced heart failure11
Circulating microRNAs in cellular and antibody-mediated heart transplant rejection11
Heart retransplantation following COVID-19 illness in a heart transplant recipient11
Cardiac allograft vasculopathy and secondary outcomes of hepatitis C-positive donor hearts at 1 year after transplantation11
First Results of Soprano: Macitentan in Patients (pts) with Pulmonary Hypertension (PH) Post-Left Ventricular Assist Device (LVAD) Implantation11
Immunologic risk stratification of pediatric heart transplant patients by combining HLAMatchmaker and PIRCHE-II11
Comparison of de novo donor-specific antibodies between living and cadaveric lung transplantation11
Safety of reduced anti-thrombotic strategy in patients with HeartMate 3 left ventricular assist device11
Intravenous bevacizumab as a novel treatment for refractory left ventricular assist device-related gastrointestinal bleeding11
Sex disparities in the current era of pediatric heart transplantation in the United States11
Residual mitral regurgitation in patients with left ventricular assist device support – An INTERMACS analysis10
Patient factors associated with left ventricular assist device infections: A scoping review10
Full recovery of right ventricular systolic function in children undergoing bilateral lung transplantation for severe PAH10
Lung transplantation disparities based on diagnosis for patients bridging to transplant on extracorporeal membrane oxygenation10
Plasma kallikrein predicts primary graft dysfunction after heart transplant10
Hemodynamic reserve predicts early right heart failure after LVAD implantation10
0.065433025360107